NCT03262727View on ClinicalTrials.gov

The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

November 23, 2017

Study Completion Date

December 19, 2017

Conditions
Systemic Lupus ErythematosusArthritic PsoriasisPsoriasisInflammatory Bowel Diseases
Interventions
DRUG

BMS-986165

Oral administration of specified dose on specified days

DRUG

Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)

Oral Contraceptive

Trial Locations (1)

33173-5426

Miami Research Associates, Miami

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03262727 - The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients | Biotech Hunter | Biotech Hunter